‘New Era’ To Begin For UK’s ILAP In 2025, With Focus On ‘Transformative’ Drugs
Some stakeholders say that the entry criteria for the licensing and access pathway have been too broad, leading to an overburdening of the scheme.
Some stakeholders say that the entry criteria for the licensing and access pathway have been too broad, leading to an overburdening of the scheme.